Annovis Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $76.3M
- Price
- $1.79
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.24%
- Volume
- 548.7K
About
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Quick stats
Shares outstanding42.5M
Computed float30.3M
Float / shares71.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001477845
Websitehttps://www.annovisbio.com
AI Summary
AI-generated1/12
majormixedearnings
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
Annovis Bio achieved full enrollment of 850 patients in its pivotal Phase 3 Alzheimer’s trial, exceeding the original target of 760 patients, with topline data expected in Q1 2027.
Financially, the company reported cash and cash equivalents of $18.7 million as of June 30, 2026, while R&D expenses surged to $12.0 million for the quarter, driving a net loss per share of $0.40.
The current cash balance compared to the roughly $14.4 million quarterly operating burn rate implies a runway of less than two quarters, highlighting an immediate need for capital raising.
Red flags
- Cash balance of $18.7M vs quarterly burn ~$14.4M implies < 2 quarters runway
- R&D expenses more than doubled year-over-year to $12.0M
- Warrant liability increased significantly to $19.9M